Shumita Sharma Deveshwar

Director of India Research
+44 203 006 3102

How can we help?

To learn more about our services get in touch on +44 20 7246 7800 or sales@trustedsources.co.uk.

Recent India research

* India: Fiscal policy puts Modi at odds with RBI, Shumita Sharma Deveshwar, 12 Oct 2017
* India: Gujarat poll to test identity vs economics, Amitabh Dubey, 5 Oct 2017
* India In Charts: A disappointingly slow recovery ahead, Shumita Sharma Deveshwar, 21 Sep 2017
* India: RBI firm on inflation, despite growth risk, Shumita Sharma Deveshwar, 14 Sep 2017
* India: Modi risks losing control of jobs narrative, Amitabh Dubey, 8 Sep 2017

See all our India research >>

India: Pharmaceutical ferment

Overview

Grand generalisations do not necessarily flow from Daiichi Sankyo's acquisition of India’s largest pharmaceutical firm, Ranbaxy. As pointed out by our trusted source – a former CEO of Ranbaxy – this deal had many company-specific causes. Yet it highlights an intensifying ferment in India's pharmaceutical sector as a combination of global and domestic factors focuses attention on generics.

As the imminent wave of patent expiries pushes Big Pharma towards generics, two types of...

* Access to this publication is restricted

Request access

If you would like to read this publication, please enter your name and email address below:

Alternatively please call us on +44 20 7183 5280, or email sales@trustedsources.co.uk.

Already registered?